3 results
Not approvedWill not start
To evaluate health related QoL under an oral cyclic treatment with physiological steroid hormones: Duogestan®.
Not approvedWill not start
The primary objective is to evaluate health related QoL under an oral sequential treatment with natural steroid hormones: Duogestan®. The secondary objective is to evaluate the bleeding patterns over a one-year period.
Approved WMOSuspended
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of platinum-based doublet…